Author： Tadesse Birkneh Tilahun Kinloch Natalie N. Baraki Bemuluyigza Lapointe Hope R. Cobarrubias Kyle D. Brockman Mark A. Brumme Chanson J. Foster Byron A. Jerene Degu Makonnen Eyasu Aklillu Eleni Brumme Zabrina L.
Publisher： MDPI
E-ISSN： 1999-4915|10|2|60-60
ISSN： 1999-4915
Source： Viruses, Vol.10, Iss.2, 2018-02, pp. : 60-60
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Clinical monitoring of pediatric HIV treatment remains a major challenge in settings where drug resistance genotyping is not routinely available. As a result, our understanding of drug resistance, and its impact on subsequent therapeutic regimens available in these settings, remains limited. We investigate the prevalence and correlates of HIV-1 drug resistance among 94 participants of the Ethiopia Pediatric HIV Cohort failing first-line combination antiretroviral therapy (cART) using dried blood spot-based genotyping. Overall, 81% (73/90) of successfully genotyped participants harbored resistance mutations, including 69% (62/90) who harbored resistance to both Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs). Strikingly, 42% of resistant participants harbored resistance to all four NRTIs recommended for second-line use in this setting, meaning that there are effectively no remaining cART options for these children. Longer cART duration and prior regimen changes were significantly associated with detection of drug resistance mutations. Replicate genotyping increased the breadth of drug resistance detected in 34% of cases, and thus is recommended for consideration when typing from blood spots. Implementation of timely drug resistance testing and access to newer antiretrovirals and drug classes are urgently needed to guide clinical decision-making and improve outcomes for HIV-infected children on first-line cART in Ethiopia.
Related content
By Bi Xiuqiong Ishizaki Azumi Nguyen Lam Van Matsuda Kazunori Pham Hung Viet Phan Chung Thi Thu Ogata Kiyohito Giang Thuy Thi Thanh Phung Thuy Thi Bich Nguyen Tuyen Thi Tokoro Masaharu Pham An Nhat Khu Dung Thi Khanh Ichimura Hiroshi
International Journal of Molecular Sciences, Vol. 17, Iss. 8, 2016-08 ,pp. :
Access to resources
Recommend
Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
By Mesplède Thibault Wainberg Mark A.
Viruses, Vol. 6, Iss. 9, 2014-08 ,pp. :
Current Perspectives on HIV-1 Antiretroviral Drug Resistance
By Iyidogan Pinar Anderson Karen S.
Viruses, Vol. 6, Iss. 10, 2014-10 ,pp. :
Access to resources